Sreyashi Basu

Sreyashi Basu

Auto-generated profile, based on publicly available information

Sreyashi Basu

James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JGJianjun Gao
Jianjun Gao
NNNeema Navai
Neema Navai
OAOmar Alhalabi
Omar Alhalabi
ASArlene Siefker-Radtke
Arlene Siefker-Radtke
MCMatthew T Campbell
Matthew T Campbell
PSPadmanee Sharma
Padmanee Sharma

16 March 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
TCTina Cascone
Tina Cascone
CLCheuk H. Leung
Cheuk H. Leung
AWAnnikka Weissferdt
Annikka Weissferdt
APApar Pataer
Apar Pataer
BCBrett W. Carter
Brett W. Carter
BSBoris Sepesi
Boris Sepesi
Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT) induce greater pathologic response rates than CT alone in patients with operable non-small cell lung cancer (NSCLC). The impact of adding ipilimumab to neoadjuvant Nivo+CT is unknown. Here we report the results and correlates of two arms of the phase 2 platform NEOSTAR trial testing neoadjuvant Nivo+CT and Ipi+Nivo+CT with major pathologic response (MPR) as the primary endpoint. MPR rates were 32.1% (7/22, 80% confidence interval (CI) 18.7–43.1%) in the Nivo+CT arm and 50% (11/22, 80% CI 34.6–61.1%) in the Ipi+Nivo+CT arm; the primary endpoint was met in both arms. In patients without known tumor EGFR/ALK alterations, MPR rates were 41.2% (7/17) and 62.5% (10/16) in the Nivo+CT and Ipi+Nivo+CT groups, respectively. No new safety signals were observed in either arm. Single-cell sequencing and multi-platform immune profiling (exploratory endpoints) underscored immune cell populations and phenotypes, including effector memory CD8+ T, B and myeloid cells and markers of tertiary lymphoid structures, that were preferentially increased in the Ipi+Nivo+CT cohort. Baseline fecal microbiota in patients with MPR were enriched with beneficial taxa, such as Akkermansia, and displayed reduced abundance of pro-inflammatory and pathogenic microbes. Neoadjuvant Ipi+Nivo+CT enhances pathologic responses and warrants further study in operable NSCLC. (ClinicalTrials.gov registration: NCT03158129.)

29 June 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RFRenata Ferrarotto
Renata Ferrarotto
MAMoran Amit
Moran Amit
PNPriyadharsini Nagarajan
Priyadharsini Nagarajan
MRM. Laura Rubin
M. Laura Rubin
YYYing Yuan
Ying Yuan
NGNeil D. Gross
Neil D. Gross
Purpose: In locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN), surgery followed by radiotherapy is standard but can be cosmetically and functionally devastating, and many patients will have recurrence. Patients and Methods: Newly diagnosed or recurrent stage III–IVA CSCC-HN patients amenable to curative-intent surgery received two cycles of neoadjuvant PD-1 inhibition. The primary endpoint was ORR per RECIST 1.1. Secondary endpoints included pathologic response [pathologic complete response (pCR) or major pathologic response (MPR; ≤10% viable tumor)], safety, DSS, DFS, and OS. Exploratory endpoints included immune biomarkers of response. Results: Of 20 patients enrolled, 7 had recurrent disease. While only 6 patients [30%; 95% confidence interval (CI), 11.9–54.3] had partial responses by RECIST, 14 patients (70%; 95% CI, 45.7–88.1) had a pCR (n = 11) or MPR (n = 3). No SAEs ocurred during or after the neoadjuvant treatment. At a median follow-up of 22.6 months (95% CI, 21.7–26.1), one patient progressed and died, one died without disease, and two developed recurrence. The 12-month DSS, DFS, and OS rates were 95% (95% CI, 85.9–100), 89.5% (95% CI, 76.7–100), and 95% (95% CI, 85.9–100), respectively. Gene expression studies revealed an inflamed tumor microenvironment in patients with pCR or MPR, and CyTOF analyses demonstrated a memory CD8+ T-cell cluster enriched in patients with pCR. Conclusions: Neoadjuvant immunotherapy in locoregionally advanced, resectable CSCC-HN is safe and induces a high pathologic response rate. Pathologic responses were associated with an inflamed tumor microenvironment.

17 June 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SGSangeeta Goswami
Sangeeta Goswami
YCYulong Chen
Yulong Chen
SASwetha Anandhan
Swetha Anandhan
PSPeter M. Szabo
Peter M. Szabo
SBSreyashi Basu
Sreyashi Basu
PSPadmanee Sharma
Padmanee Sharma
A combination of ARID1A mutation and CXCL13 expression in baseline tumor tissues improves predictive capability for patients with mUCC receiving ICT.

18 October 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
HAHussein A. Abbas
Hussein A. Abbas
DHDapeng Hao
Dapeng Hao
KTKatarzyna Tomczak
Katarzyna Tomczak
PBPraveen Barrodia
Praveen Barrodia
JIJin Seon Im
Jin Seon Im
AFAndrew Futreal
Andrew Futreal
In contrast to the curative effect of allogenic stem cell transplantation in acute myeloid leukemia via T cell activity, only modest responses are achieved with checkpoint-blockade therapy, which might be explained by T cell phenotypes and T cell receptor (TCR) repertoires. Here, we show by paired single-cell RNA analysis and TCR repertoire profiling of bone marrow cells in relapsed/refractory acute myeloid leukemia patients pre/post azacytidine+nivolumab treatment that the disease-related T cell subsets are highly heterogeneous, and their abundance changes following PD-1 blockade-based treatment. TCR repertoires expand and primarily emerge from CD8+ cells in patients responding to treatment or having a stable disease, while TCR repertoires contract in therapy-resistant patients. Trajectory analysis reveals a continuum of CD8+ T cell phenotypes, characterized by differential expression of granzyme B and a bone marrow-residing memory CD8+ T cell subset, in which a population with stem-like properties expressing granzyme K is enriched in responders. Chromosome 7/7q loss, on the other hand, is a cancer-intrinsic genomic marker of PD-1 blockade resistance in AML. In summary, our study reveals that adaptive T cell plasticity and genomic alterations determine responses to PD-1 blockade in acute myeloid leukemia.

20 August 2025 in Nature
Verified
Journal Article
Open access
PDF file
EBErez N. Baruch
Erez N. Baruch
FGFrederico Omar Gleber-Netto
Frederico Omar Gleber-Netto
PNPriyadharsini Nagarajan
Priyadharsini Nagarajan
XRXiayu Rao
Xiayu Rao
SAShamima Akhter
Shamima Akhter
Moran AmitMoran Amit
Moran Amit
Perineural invasion (PNI) is a well-established factor of poor prognosis in multiple cancer types1, yet its mechanism remains unclear. Here we provide clinical and mechanistic insights into the role of PNI and cancer-induced nerve injury (CINI) in resistance to anti-PD-1 therapy. Our study demonstrates that PNI and CINI of tumour-associated nerves are associated with poor response to anti-PD-1 therapy among patients with cutaneous squamous cell carcinoma, melanoma and gastric cancer. Electron microscopy and electrical conduction analyses reveal that cancer cells degrade the nerve fibre myelin sheets. The injured neurons respond by autonomously initiating IL-6- and type I interferon-mediated inflammation to promote nerve healing and regeneration. As the tumour grows, the CINI burden increases, and its associated inflammation becomes chronic and skews the general immune tone within the tumour microenvironment into a suppressive and exhaustive state. The CINI-driven anti-PD-1 resistance can be reversed by targeting multiple steps in the CINI signalling process: denervating the tumour, conditional knockout of the transcription factor mediating the injury signal within neurons (Atf3), knockout of interferon-α receptor signalling (Ifnar1−/−) or by combining anti-PD-1 and anti-IL-6-receptor blockade. Our findings demonstrate the direct immunoregulatory roles of CINI and its therapeutic potential.